Current partner codePEPTIDESDE
NCT00460811·Phase 2·INTERVENTIONAL

Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Status

Completed

Phase

Phase 2

Enrollment

420

Locations

85

Results

Posted

Publications

2

Study summary

What the protocol is testing.

The purpose of this study is to determine the safety, efficacy, and dose response of a range of oral doses of linaclotide administered to patients meeting criteria for IBS-C.

Interventions

Treatment arms and agents.

DRUG

Linaclotide Acetate

Oral, once daily

DRUG

Matching placebo

Oral, once daily

Timeline

From registration to results.

  1. First posted

    Apr 16, 2007

  2. Study start

    Apr 2007

  3. Primary completion

    Feb 2008

  4. Study completion

    Apr 2008

  5. Results posted

    Jan 30, 2013

  6. Registry updated

    Feb 4, 2013

Outcomes

What the study measures.

Primary outcomes

Change From Baseline in the Weekly Normalized Complete Spontaneous Bowel Movement (CSBM) Rate During Weeks 1 Through 12 of the Treatment Period

Time frame · Change from Baseline to Week 12

The change in the weekly normalized CSBM Rate during Weeks 1 through 12 of the Treatment Period from the weekly normalized CSBM Rate obtained during the Pretreatment Period. The CSBM rate was normalized based on the number of CSBMs occurring in that week, adjusting for differences in the duration of the week and black-out periods (time not covered due to a missed IVRS call) versus 7x24 hours.

Secondary outcomes

CSBM 75% Responder for the Treatment Period (Based on the Normalized Rate)

Time frame · Change from Baseline to Week 12

For each week of the Treatment and Posttreatment Periods, a patient was considered a CSBM Responder if for that week the patient 1) completed ≥ 4 days of IVRS questions, 2) had a CSBM rate of ≥ 3 for the week, and 3) had an increase in CSBM rate of ≥ 1 from the baseline weekly CSBM rate.

Change From Baseline in the Weekly Normalized SBM Rate for the Treatment Period

Time frame · Change from Baseline to Week 12

SBMs were measured daily during the treatment period by patient calls to the IVRS.

Change From Baseline in Stool Consistency (7-point Ordinal BSFS) for the Treatment Period

Time frame · Change from Baseline to Week 12

Stool consistency analyses were performed using the 7-point Bristol Stool Form Scale (BSFS), whereby a score of 1 = separate hard lumps like nuts (difficult to pass); 2 = sausage shaped but lumpy; 3 = like a sausage but with cracks on surface; 4 = like a sausage or snake, smooth and soft; 5 = soft blobs with clear-cut edges (passed easily); 6 = fluffy pieces with ragged edges, a mushy stool; and 7 = watery, no solid pieces (entirely liquid).

Change From Baseline in Straining (5-point Ordinal Scale) for the Treatment Period

Time frame · Change from Baseline to Week 12

Straining was assessed using a 5-point ordinal scale, whereby a score of 1 = not at all, 2 = a little bit, 3 = a moderate amount, 4 = a great deal, and 5 = an extreme amount.

Change From Baseline in Degree of Relief of Irritable Bowel Syndrome (IBS) Symptoms (7-point Balanced Scale) for the Treatment Period

Time frame · Change from Baseline to Week 12

Patients provided a weekly assessment of Degree of Relief of IBS Symptoms using a 7-point balanced scale (1=completely relieved, 2=considerably relieved, 3=somewhat relieved, 4=unchanged, 5=somewhat worse, 6=considerably worse, 7=as bad as I can imagine).

Change From Baseline in Abdominal Pain (5-point Ordinal Scale) for the Treatment Period

Time frame · Change from Baseline to Week 12

During the study, patients provided their self assessment of abdominal pain using a 5-point ordinal scale (1=none, 2=mild, 3=moderate, 4=severe, 5=very severe

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
Not reported
Sex
ALL
Healthy volunteers
No

Inclusion Criteria: * Must not be pregnant or breastfeeding and agree to use birth control; * Completion of a negative colonoscopy as per American Gastroenterology Association (AGA) criteria and no clinically-significant laboratory or physical examination findings; * Meets protocol-defined criteria for IBS-C, including stool frequency, straining, stool consistency, abdominal pain, and abdominal discomfort criteria; * Demonstrates English fluency and has access to a touch-tone telephone. Exclusion Criteria: * Recent history of mushy or watery stools; * Various medical conditions, medical histories, or family medical histories that would not make the patient a good candidate for the study; * Clinically-significant alarm symptoms; * Secondary causes of constipation or evacuation disorders; * Surgery to the gastrointestinal tract; * Usage of prohibited medications.

Study locations

85 registered sites.

Canada · United States. Showing up to 24 locations stored in the fast local snapshot.

Microbia Investigational Site

Huntsville, Alabama, United States

Microbia Investigational Site

Chandler, Arizona, United States

Microbia Investigational Site

Tuscon, Arizona, United States

Microbia Investigational Site

Sherwood, Arkansas, United States

Microbia Investigational Site

Anaheim, California, United States

Microbia Investigational Site

Garden Grove, California, United States

Microbia Investigational Site

Sacramento, California, United States

Microbia Investigational Site

San Diego, California, United States

Microbia Investigational Site

Bristol, Connecticut, United States

Microbia Investigational Site

Boynton Beach, Florida, United States

Microbia Investigational Site

Dunedin, Florida, United States

Microbia Investigational Site

Largo, Florida, United States

Microbia Investigational Site

Ocala, Florida, United States

Microbia Investigational Site

Port Orange, Florida, United States

Microbia Investigational Site

Stuart, Florida, United States

Microbia Investigational Site

Tampa, Florida, United States

Microbia Investigational Site

Stockbridge, Georgia, United States

Microbia Investigational Site

Libertyville, Illinois, United States

Microbia Investigational Site

Peoria, Illinois, United States

Microbia Investigational Site

Clive, Iowa, United States

Microbia Investigational Site

Davenport, Iowa, United States

Microbia Investigational Site

Mission, Kansas, United States

Microbia Investigational Site

Shawnee, Kansas, United States

Microbia Investigational Site

Baton Rouge, Louisiana, United States

Related trials

More studies on Linaclotide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.